Clinical Trial Update: HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for HS-20089 injection in platinum-resistant recurrent epithelial ovarian cancer; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• HS-20089

Snippet

Sponsor: Hansoh BioMedical R&D Company | Conditions: Ovarian Cancer | Phase 3 | Status: RECRUITING